Published in Eur Psychiatry on April 01, 2004
Risperidone- and aripiprazole-induced leukopenia: a case report. Prim Care Companion J Clin Psychiatry (2008) 0.88
A case with neutropenia related with the use of various atypical antipsychotics. Psychiatry Investig (2013) 0.85
Morning pseudoneutropenia during risperidone treatment. BMJ Case Rep (2009) 0.75
Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report. BMC Psychiatry (2016) 0.75
Risperidone-induced reversible neutropenia. Neuropsychiatr Dis Treat (2017) 0.75
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res (2006) 1.66
Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res (2010) 1.52
Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophr Res (2009) 1.43
Diffusion tensor imaging in the early phase of schizophrenia: what have we learned? J Psychiatr Res (2010) 1.32
Effectiveness of selection in medical school admissions: evaluation of the outcomes among freshmen. Med Educ (2007) 1.28
Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int J Methods Psychiatr Res (2012) 1.21
The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions. Schizophr Res (2006) 1.18
Changes in cortisol and DHEA plasma levels after psychotherapy for PTSD. Psychoneuroendocrinology (2007) 1.14
Whither the attenuated psychosis syndrome? Schizophr Bull (2012) 1.12
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull (2014) 1.10
Disability in people clinically at high risk of psychosis. Br J Psychiatry (2010) 1.10
Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. Schizophr Res (2011) 1.10
Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab (2007) 1.06
Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res (2012) 1.05
White matter fibertracking in first-episode schizophrenia, schizoaffective patients and subjects at ultra-high risk of psychosis. Neuropsychobiology (2008) 1.02
HPA- and HPT-axis alterations in chronic posttraumatic stress disorder. Psychoneuroendocrinology (2006) 1.02
Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res (2011) 1.02
Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry (2010) 1.00
Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol (2011) 1.00
White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia. Schizophr Res (2011) 0.94
Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. Aust N Z J Psychiatry (2010) 0.93
Insight in psychosis: relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness. Schizophr Bull (2010) 0.92
AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur J Nucl Med Mol Imaging (2008) 0.91
Pericardial and bilateral pleural effusion associated with clozapine treatment. Eur Psychiatry (2004) 0.90
Off-label second generation antipsychotics for impulse regulation disorders: a review. Psychopharmacol Bull (2010) 0.88
Polyunsaturated fatty acid concentration predicts myelin integrity in early-phase psychosis. Schizophr Bull (2012) 0.88
Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode. Biol Psychiatry (2010) 0.88
Delirium subtype identification and the validation of the Delirium Rating Scale--Revised-98 (Dutch version) in hospitalized elderly patients. Int J Geriatr Psychiatry (2006) 0.87
A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation. Biol Psychiatry (2013) 0.87
Schizophrenia spectrum disorders in later life: prevalence and distribution of age at onset and sex in a dutch catchment area. Am J Geriatr Psychiatry (2012) 0.86
Adult attachment and psychotic phenomenology in clinical and non-clinical samples: a systematic review. Psychol Psychother (2013) 0.86
The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia. Schizophr Bull (2013) 0.86
White matter connectivity and psychosis in ultra-high-risk subjects: a diffusion tensor fiber tracking study. Psychiatry Res (2010) 0.86
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. J Clin Psychiatry (2011) 0.85
Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Res (2013) 0.85
Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. PLoS One (2011) 0.85
Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology (2009) 0.85
The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacol Bull (2008) 0.85
Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur Neuropsychopharmacol (2006) 0.85
Obsessive-compulsive symptoms in first episode psychosis and in subjects at ultra high risk for developing psychosis; onset and relationship to psychotic symptoms. Aust N Z J Psychiatry (2010) 0.85
Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Curr Pharm Des (2012) 0.85
Reduced context effects on retrieval in first-episode schizophrenia. PLoS One (2010) 0.84
Cannabis use in patients with a first psychotic episode and subjects at ultra high risk of psychosis: impact on psychotic- and pre-psychotic symptoms. Aust N Z J Psychiatry (2010) 0.84
Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. Neuropsychopharmacology (2007) 0.84
Factor analysis of the scale of prodromal symptoms: differentiating between negative and depression symptoms. Psychopathology (2011) 0.84
Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. Int Clin Psychopharmacol (2009) 0.84
Cognitive impairment in late life schizophrenia and bipolar I disorder. Int J Geriatr Psychiatry (2012) 0.84
Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients. PLoS One (2012) 0.84
Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. Bipolar Disord (2013) 0.84
Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity? Psychopharmacol Bull (2009) 0.84
Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Hum Psychopharmacol (2008) 0.84
Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Psychopharmacol Bull (2008) 0.84
Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics (2005) 0.83
The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val¹⁵⁸Met polymorphism. Schizophr Res (2013) 0.83
Relationship between working-memory network function and substance use: a 3-year longitudinal fMRI study in heavy cannabis users and controls. Addict Biol (2013) 0.83
Social functioning among older community-dwelling patients with schizophrenia: a review. Am J Geriatr Psychiatry (2010) 0.83
Dopaminergic modulation of the human reward system: a placebo-controlled dopamine depletion fMRI study. J Psychopharmacol (2010) 0.83
Subjective experiences during dopamine depletion. Am J Psychiatry (2005) 0.83
History of trauma and the association with baseline symptoms in an Ultra-High Risk for psychosis cohort. Psychiatry Res (2013) 0.82
Transition to first episode psychosis in ultra high risk populations: does baseline functioning hold the key? Schizophr Res (2012) 0.82
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Can J Psychiatry (2008) 0.82
Auditory ERP components before and after transition to a first psychotic episode. Biol Psychol (2011) 0.82
Sensory gating in subjects at ultra high risk for developing a psychosis before and after a first psychotic episode. World J Biol Psychiatry (2012) 0.81
Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review. Aust N Z J Psychiatry (2011) 0.81
Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.81
Cessation of cannabis use by patients with recent-onset schizophrenia and related disorders. Psychopharmacol Bull (2008) 0.81
Theory of mind, insecure attachment and paranoia in adolescents with early psychosis and healthy controls. Aust N Z J Psychiatry (2013) 0.81
Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Arch Gen Psychiatry (2003) 0.80
Annual incidence rate of schizophrenia and schizophrenia spectrum disorders in a longitudinal population-based cohort study. Soc Psychiatry Psychiatr Epidemiol (2013) 0.80
Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis. Eur Neuropsychopharmacol (2012) 0.80
Associations between the Five-Factor Model personality traits and psychotic experiences in patients with psychotic disorders, their siblings and controls. Psychiatry Res (2013) 0.80
The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area. BMC Psychiatry (2008) 0.80
Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PLoS One (2013) 0.80
Semantic fluency deficits and reduced grey matter before transition to psychosis: a voxelwise correlational analysis. Psychiatry Res (2011) 0.80
Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study. Eur Neuropsychopharmacol (2013) 0.79
Self-disturbance in schizophrenia: a phenomenological approach to better understand our patients. Prim Care Companion CNS Disord (2013) 0.79
Effects of cannabis use on event related potentials in subjects at ultra high risk for psychosis and healthy controls. Int J Psychophysiol (2013) 0.78
Feasibility of mindfulness-based therapy in patients recovering from a first psychotic episode: a pilot study. Early Interv Psychiatry (2012) 0.78
The care needs of elderly patients with schizophrenia spectrum disorders. Am J Geriatr Psychiatry (2013) 0.78
Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl) (2004) 0.77
Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis. Biol Psychiatry (2011) 0.77
Processing of facial and nonsocial information is differentially associated with severity of symptoms in patients with multiepisode schizophrenia. J Nerv Ment Dis (2015) 0.77
Quality of life in patients with psychotic disorders: impact of symptoms, personality, and attachment. J Nerv Ment Dis (2014) 0.77
To cut a short test even shorter: reliability and validity of a brief assessment of intellectual ability in schizophrenia--a control-case family study. Cogn Neuropsychiatry (2012) 0.77
Informed consent from behaviourally disturbed patients. Lancet (2002) 0.77
Catechol-O-methyltransferase gene and obsessive-compulsive symptoms in patients with recent-onset schizophrenia: preliminary results. Psychiatry Res (2007) 0.77
Subjective effects of cannabis before the first psychotic episode. Aust N Z J Psychiatry (2009) 0.77
Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol (2011) 0.77
Qualitative and quantitative aspects of information processing in first psychosis: latent class analyses in patients, at-risk subjects, and controls. Psychophysiology (2014) 0.77
Subjective quality of life and its determinants in a catchment area based population of elderly schizophrenia patients. Schizophr Res (2013) 0.77
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. J Clin Psychopharmacol (2008) 0.76
Psychometric evaluation of the Subjective Well-being Under Neuroleptic Treatment Scale (SWN) in patients with schizophrenia, their relatives and controls. Psychiatry Res (2012) 0.76
Symptomatic remission and associated factors in a catchment area based population of older patients with schizophrenia. Schizophr Res (2011) 0.76
Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis. Psychopathology (2006) 0.76
Quantitative and qualitative symptomatic differences in individuals at Ultra-High Risk for psychosis and healthy controls. Psychiatry Res (2013) 0.76
Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. Psychopharmacol Bull (2009) 0.76
Comparable dopamine 2 receptor occupancy. Am J Psychiatry (2002) 0.75
Familial Aggregation of Non-Hodgkin's Lymphoma (NHL). A Case Report. Hered Cancer Clin Pract (2006) 0.75
Elevated homocysteine levels in schizophrenia. Am J Psychiatry (2004) 0.75